Influence of HLA-DQA1*05 on the loss of response to anti-TNF treatment in inflammatory bowel disease. Spanish cohort of real clinical practice

Gastroenterol Hepatol. 2024 Oct;47(8):869-871. doi: 10.1016/j.gastrohep.2024.01.005. Epub 2024 Jan 22.

[Article in English, Spanish]

Authors

Jorge Pérez Pérez¹, Jaime Escobar Ortiz², Ana Isabel Franco Moreno³, María Del Rocío Plaza Santos², Marta Castillo Pradillo², Ángel Ponferrada Díaz²

Affiliations

¹ Infanta Leonor University Hospital, Gastroenterology and Hepatology, Madrid, Spain. Electronic address: [email protected].
² Infanta Leonor University Hospital, Gastroenterology and Hepatology, Madrid, Spain.
³ Infanta Leonor University Hospital, Internal Medicine, Madrid, Spain.

PMID: 38266819
DOI: 10.1016/j.gastrohep.2024.01.005

No abstract available

Publication types

Letter
Case Reports

MeSH terms

Adalimumab / therapeutic use
Adult
Cohort Studies
Colitis, Ulcerative / drug therapy
Crohn Disease / drug therapy
Female
HLA-DQ alpha-Chains* / genetics
Humans
Inflammatory Bowel Diseases / drug therapy
Inflammatory Bowel Diseases / genetics
Infliximab / therapeutic use
Male
Middle Aged
Spain
Treatment Failure
Tumor Necrosis Factor-alpha* / antagonists & inhibitors

Substances

HLA-DQ alpha-Chains
HLA-DQA1 antigen
Tumor Necrosis Factor-alpha
Infliximab
Adalimumab